NUS scientists harness magnetic pulses to reprogram immune cells to fight breast cancer

An innovative approach for breast cancer treatment uses localised and non-invasive pulsed electromagnetic fields to reprogram immune cells, turning them from tumour helpers to cancer killers

SINGAPORE, Sept. 14, 2026 /PRNewswire/ -- Researchers from the National University of Singapore (NUS) have demonstrated an innovative approach for targeted breast cancer therapy using pulsed electromagnetic fields (PEMFs). The NUS team successfully reprogrammed tumour-associated macrophages (TAMs), a corrupted class of immune cells that typically promote cancer growth, into an active anti-tumour state that attacks and destroys cancer cells.

The study, led by Associate Professor Alfredo Franco-Obregón from the Department of Surgery at the NUS Yong Loo Lin School of Medicine and the NUS Institute for Health Innovation & Technology, was published in the journal Smart Medicine on 4 June 2026. This discovery builds on their previous work, where they showed that brief PEMF exposure enhances uptake of doxorubicin (DOX), a chemotherapy drug, by breast cancer cells.

PEMF therapy applies intermittent, low-intensity magnetic pulses to targeted regions of the body over a short period of time. Assoc Prof Franco-Obregón has previously explored the effect of PEMFs on muscle development and oncology. In their latest study, the NUS team demonstrated that even without chemotherapy, PEMFs completely eradicated tumours in 75 per cent of tested preclinical models after just four 30-minute sessions.

"Our study represents a major advancement in breast cancer treatment by demonstrating the potential of PEMFs as a stand-alone, drug-free therapy, offering a possible future where patients could avoid chemotherapy and its debilitating side effects," said Assoc Prof Franco-Obregón.

Breast cancer cases are projected to rise by a third, from 2.3 million in 2023 to more than 3.5 million by 2050, while annual deaths may nearly double from 764,000 to nearly 1.4 million. Cancer treatment faces challenges such as tumour heterogeneity, drug resistance, and treatment-related toxicities. Approaches targeting TAMs also faced difficulties such as off-target effects. The growing burden underscores the urgent need for innovative therapies to improve patient outcomes and save lives.

From cancer's friends to foes

Breast cancer occurs when cells in the breast mutate and grow uncontrollably, forming a solid tumour. These cancer cells recruit and hijack nearby immune cells, corrupting them to protect the tumour, accelerate tumour growth, and encourage the spread of cancer (metastasis). Prominent among these recruited immune cells are TAMs, which are abundant in nearly all solid tumours.

There are two primary types of macrophages, M1 and M2. M1 macrophages are pro-inflammatory – the "soldiers" that eliminate threats like bacteria and viruses. M2 macrophages are anti-inflammatory – the "medics" that orchestrate wound healing and tissue repair once threats are cleared. Cancer cells corrupt most TAMs into adopting the M2 "medic" state, suppressing immune attacks against the tumour while facilitating tumour growth and metastasis.

The key to this macrophage reprogramming lies in a protein called TRPC1 (Transient Receptor Potential Canonical 1), which regulates the M1 state. Crucially, TRPC1 also allows cells to sense and respond to magnetic fields. In their experiments, the NUS team confirmed that a brief 10-minute exposure to PEMFs activated TRPC1 channels on M2-like TAMs, setting off a signalling cascade that converted them to the M1 state – essentially turning TAMs from helpful "medics" to aggressive cancer-killing "soldiers". These activated TAMs then selectively target cancer cells while sparing healthy tissue. Furthermore, the same magnetic signature disrupts cancer's ability to hijack TAMs, altering the TAM-cancer communication loop in both directions.

"We have identified a molecular "switch", the specific cell signalling pathway that allows us to reprogram TAMs. Once reprogrammed, these immune cells actively hunt and devour cancer cells, obliterating the tumour," said Assoc Prof Franco-Obregón. "With the non-invasive and targeted nature of PEMF therapy, we hope to provide patients an effective and safe alternative treatment, with fewer undesirable side effects."

Pulses of hope for cancer patients

Assoc Prof Franco-Obregón shared that the same PEMF device used in this study has just successfully completed Phase 1 clinical trials, demonstrating its safety in humans. The team is now seeking partners to conduct Phase 2 efficacy trials to evaluate how well the PEMF treatment works in patients and to further advance its development towards clinical use.

"Since we previously showed that PEMFs selectively increased the uptake of DOX in breast cancer cells, we will be evaluating if our PEMF immunotherapy can work synergistically with chemotherapy for better results," added Assoc Prof Franco-Obregón. "As the immune cells we reprogram are commonly found in most solid tumours, we are optimistic that our PEMF therapy could potentially be a complementary treatment for other cancers beyond breast cancer."

Read more: https://news.nus.edu.sg/magnetic-pulses-reprogram-immune-cells-to-fight-breast-cancer

SOURCE National University of Singapore

Share this article

Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO

CHENGDU, China, Sept. 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational study of its novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate (ADC) trastuzumab botidotin (舒泰莱®) in HER2-positive unresectable or metastatic breast cancer (BC) have been published in Journal of Clinical Oncology (JCO, impact factor (IF)=44.7). Professor Xichun Hu and Professor Hongxia Wang of Fudan University Shanghai Cancer Center, and Dr. Junyou Ge, Director of the National Engineering Research Center of Targeted Biologics act as the co-senior authors. Professor Jian Zhang of Fudan University Shanghai Cancer Center, Professor Quchang Ouyang of Hunan Cancer Hospital, Professor Qingyuan Zhang of Harbin Medical University Cancer Hospital, Professor Huihui Li of Cancer Hospital of Shandong First Medical University, and Professor Xu Wang of Tianjin Medical University Cancer Institute and Hospital act as the co-first authors. These findings had previously been selected as a Late-Breaking Abstract (LBA) and presented as an oral presentation at the 2025 European Society for Medical Oncology (ESMO) Congress.

This randomized, open-label, multicenter phase III study was designed to evaluate the efficacy and safety of trastuzumab botidotin monotherapy versus trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic BC who had received prior trastuzumab and taxane-containing regimens. A total of 365 patients were randomized 1:1 to receive trastuzumab botidotin or T-DM1. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review (BICR), and secondary endpoints included overall survival (OS), objective response rate (ORR), and duration of response (DoR).

As of the data cutoff date of April 26, 2025, with a median follow-up of 14.9 months, efficacy results showed:

- Median PFS was significantly prolonged in the trastuzumab botidotin group compared with the T-DM1 group (11.1 months vs. 4.4 months; hazard ratio (HR) = 0.39) (Figure A), meeting the primary endpoint of the study; consistent PFS benefit was observed across all prespecified subgroups (Figure B).

-  Trastuzumab botidotin group demonstrated deeper and more durable tumor responses compared with T-DM1 group, with an ORR of 76.9% vs. 53.0% and a median DoR of 12.2 months vs. 5.7 months (Figure C).

- OS data were not mature in both groups, but an OS benefit trend was observed in trastuzumab botidotin group, demonstrating a 38% reduction in the risk of death (Figure D).

In terms of safety, patients in the trastuzumab botidotin group had a low incidence of interstitial lung disease (ILD), and the incidences of hematologic, hepatic, and gastrointestinal toxicities were notably lower than those in the T-DM1 group, along with lower rates of serious adverse events (SAEs) and treatment discontinuations. The most common treatment-related adverse events (TRAEs) in trastuzumab botidotin group were ocular events, which could be recovered or reversed after management with standardized strategies.

The publication of the phase III results for trastuzumab botidotin in Journal of Clinical Oncology marks a major international academic breakthrough for a domestically developed HER2 ADC backed by high-level clinical evidence. This is the first phase III trial in China for a HER2 ADC compared head-to-head with T-DM1 with positive results. The data showed that trastuzumab botidotin demonstrated improvements in key efficacy endpoints including PFS, ORR, and DoR, along with a favorable safety profile. Based on these positive results, trastuzumab botidotin has been approved by China's National Medical Products Administration (NMPA) for the treatment of second-line or later HER2-positive BC, becoming the first domestically developed HER2 ADC approved for this indication in China and providing a new treatment option for patients with HER2-positive advanced breast cancer.

About Trastuzumab botidotin(舒泰莱®)

Trastuzumab botidotin is a differentiated HER2 ADC to treat advanced HER2+ solid tumors. As an innovative HER2 ADC developed by the Company, it conjugates a novel, monomethyl auristatin F (MMAF) derivative (a highly cytotoxic tubulin inhibitor, Duo-5) via a stable, enzyme-cleavable linker to a HER2 monoclonal antibody with a DAR of 2. Trastuzumab botidotin specifically binds to HER2 on the surface of tumor cells and is internalized by tumor cells, releasing the toxin molecule Duo-5 inside the cell. Duo-5 induces tumor cell cycle arrest in the G2/M phase, leading to tumor cell apoptosis. After targeting HER2, trastuzumab botidotin can also inhibit the HER2 signaling pathway; it has antibody-dependent cell-mediated cytotoxicity (ADCC) activity.

Based on the results of a multi-center, randomized, open-label, controlled Phase 3 KL166-III-06 study, trastuzumab botidotin was approved for marketing by the NMPA for adult patients with unresectable or metastatic HER2 positive BC who have received one or more prior anti-HER2 therapy. At a pre-specified interim analysis, trastuzumab botidotin monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of PFS as assessed by the BICR compared with T-DM1; the beneficial trend for OS of trastuzumab botidotin was also observed.

Currently, the Company has initiated an open, multi-center Phase 2 clinical study of trastuzumab botidotin in the treatment of HER2+ unresectable or metastatic BC that previously received a topoisomerase inhibitor payload ADC.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 2 projects with 3 indications are in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

SOURCE Kelun-Biotech

Share this article

- Patrick Delany appointed Chief Operating Officer to accelerate subscriber and revenue growth and drive tight integration across DAZN's divisions.

- Alex Gersh joins DAZN as Chief Financial Officer to lead financial strategy, capital allocation and group performance through DAZN's next phase.

- Darren Waterman, Chief Financial Officer appointed to the new role of Chief Business Officer to spearhead DAZN's global partnerships, distribution and corporate transactions.

LONDON, Sept. 14, 2026 /PRNewswire/ -- DAZN, the world's leading sports entertainment platform, today announced three appointments to further strengthen its executive leadership team and drive the group's next phase of profitable growth. All three leaders report to Shay Segev, Chief Executive Officer, effective immediately.

The appointments come in a pivotal year for DAZN, with the company building on strong momentum achieved in 2025 during which it acquired Foxtel Group, delivered the FIFA Club World Cup watched by hundreds of millions of fans globally, and reached profitability for the first time. In 2026, DAZN has continued to scale, announcing acquisitions of ViewLift and EverPass to extend its platform capabilities and rights relationships, renewing premium rights in core markets, adding FIFA+ to the DAZN platform, and most recently, rapidly building out a regional sports business in the US. All three appointments will strengthen DAZN's leadership team as it looks ahead.

Patrick Delany is appointed Chief Operating Officer, based in London. He will have end-to-end responsibility for the day-to-day trading performance of DAZN, driving subscriber and revenue growth across the company. He will oversee the running of DAZN's operational businesses, pricing and packaging, rights renewals and rights-holder relationships, content production and execution, and advertising and sponsorship.

Delany brings more than three decades of experience across sports, media and digital subscription businesses. As CEO of Foxtel Group since 2018, and previously CEO of Fox Sports Australia, he led the transformation of one of Australia's largest media businesses, including the launch and growth of Kayo Sports and BINGE. Most recently, following its acquisition by DAZN, Delany led the successful integration of Foxtel into DAZN, creating DAZN Australia, a company with products used in one of every two Australian homes.

Alex Gersh will join DAZN as Chief Financial Officer, succeeding Darren Waterman. Gersh brings more than 25 years of international financial leadership across sectors including sports, betting, technology and telecoms at both private and publicly listed companies.

At Sportradar, as CFO, he led the company through its successful NASDAQ listing. Prior to that he was CFO of Betfair and subsequently Paddy Power Betfair following their merger. With deep experience in high-growth digital businesses, public markets and large-scale integration, Gersh will further strengthen DAZN's financial strategy, capital allocation, performance, and long-term value creation.

Darren Waterman is appointed to the new role of Chief Business Officer spearheading strategic commercial, partnership, and transformational opportunities for the group. As DAZN's Chief Financial Officer since 2022, Waterman has led DAZN's Finance function and the group's commercial and corporate development through a period of exceptional growth, with the company reaching profitability in 2025 setting a solid foundation for its next chapter.

Shay Segev, DAZN Group CEO, said: "DAZN is entering an exciting new chapter of profitable growth, during which we will build on the strong momentum we have created in the business. Our built-for-sport platform is now available in more than 200 markets, connecting millions of fans across the world to the sports they love through immersive experiences that go far beyond broadcast. The stage is set for our strengthened leadership team to intensify our mission to build the world's best sports entertainment platform for fans, rights holders and partners."

DAZN also confirmed that Alice Mascia, after four successful years as CEO in the DACH region, has decided to leave DAZN at the end of year. Felix Krause returns to DAZN with immediate effect as Deputy CEO, DACH and will become CEO, DACH on 1 January 2027.

About DAZN

DAZN, the world's leading sports entertainment platform, streams more than 150,000 live events annually and is available in over 200 markets worldwide. DAZN is the home of football, boxing and MMA, as well as the NFL Game Pass and NHL.TV internationally. The platform features the biggest sports and leagues from around the world – Bundesliga, Serie A, LALIGA, Ligue 1, Formula 1, NBA, Moto GP, and many more.

Built on a highly scalable, cloud-based architecture, DAZN's platform is purpose-built for sport. From latency optimised streaming to adaptive delivery that optimises quality across devices and connectivity, DAZN delivers the highest-quality viewing experience at global scale. The platform integrates advanced data, hyper-personalisation, and AI-enabled features to enhance discovery, interactivity, and fan engagement. DAZN is an ecosystem of content, products, and features where fans can watch, play, buy and connect in real time.

DAZN is transforming the way people enjoy sport. Fans can enjoy live and on-demand sports content anywhere and on any device – only on DAZN. The company partners with leading pay-TV operators, ISPs and Telcos worldwide to maximise sports exposure to a broad audience. DAZN is a global, privately owned company, founded in 2016, with more than 4,000 employees. For more information on DAZN, visit www.dazngroup.com.

SOURCE DAZN

Share this article

Aitech Introduces New C165 Rugged Single Board Computer to Help Defense Programs Build and Modernize Fielded VME Systems

New 6U VME SBC Delivers Modern Intel Computing and Graphics, SWaP Optimization and Secure High-Capacity Storage While Preserving Existing Infrastructure and Reducing Modernization Risk

NATIONAL HARBOR, Md., Sept. 14, 2026 /PRNewswire/ -- (AFA Air, Space & Cyber Conference, Booth MB400) -- Aitech, a global leader in AI-powered rugged embedded computing and connectivity solutions for defense and space applications, today announced the C165 Rugged 6U VME Single Board Computer (SBC), helping defense and aerospace organizations build or modernize mission-critical systems while preserving proven VME infrastructure already deployed across air, land and naval platforms.

As military programs face increasing pressure to improve performance, strengthen cybersecurity and address component obsolescence, many continue to rely on fielded VME architectures that remain operationally effective but cannot easily absorb the cost, schedule disruption and technical risk of a complete platform redesign. The C165 enables program teams to modernize computing capabilities within existing systems, extending platform life and accelerating technology refresh efforts without requiring migration to a new architecture.

Aitech is showcasing the new C165 SBC, along with its mission-ready computing and connectivity solutions that help modernize air, space and defense platforms, at the Air & Space Forces Association Air, Space & Cyber Conference from Sept. 14-16 in National Harbor, Maryland in booth MB400.

"Defense customers need practical modernization solutions that improve mission capability while minimizing program risk," said Alex Trigoub, product manager, Aitech. "The C165 delivers modern, power-optimized Intel processing, powerful integrated GPU, advanced cybersecurity, versatile I/O and high-capacity secure storage in a rugged 6U VME form factor, allowing customers to enhance performance, address obsolescence challenges and extend the operational life of deployed systems without re-architecting their platforms, while also minimizing upgrade and operational costs."

The C165 reflects Aitech's commitment to helping customers modernize and sustain mission-critical systems through a combination of proven technology assets, mission-specific engineering expertise and long-term lifecycle support. As a pin-compatible successor to Aitech's C164 and C163 SBCs, the C165 provides an efficient upgrade path that helps customers manage technology obsolescence while preserving past investments in qualified hardware, software and platform infrastructure.

Built on the SWaP-optimized 11th Gen Intel® Core™ i7-1185GRE Tiger Lake UP3 processor with integrated Intel® Iris® Xe graphics, the C165 delivers significantly higher compute and graphics performance than previous-generation VME solutions. It enables system integrators to support increasingly demanding workloads, including mission computing, ISR processing, video analytics and sensor-driven applications, while maintaining compatibility with existing VME deployments.

Beyond performance gains, the C165 addresses the growing cybersecurity and data management requirements of modern defense programs. The board supports up to 32GB of LPDDR4X memory and up to 4TB of secure NVMe storage while incorporating Aitech's AiSecure™ cybersecurity framework, including TPM 2.0, Secure Boot, Intel Boot Guard, encrypted storage and secure erase capabilities to help protect mission-critical data and system integrity.

Key Features

- 11th Gen Intel Core i7-1185GRE Tiger Lake UP3 processor

- Intel Iris Xe graphics with 96 execution units

- 2x CPU performance/watt improvement over previous-generation Aitech VME platforms

- More than 2.5x graphics performance improvement

- Up to 32GB LPDDR4X-4267 memory with in-band ECC for optimization of memory-intensive workloads

- Up to 4TB self-encrypted NVMe SSD with Quick Erase and Secure Erase

- AiSecure cybersecurity framework with TPM 2.0, Secure Boot and Intel Boot Guard support

- Support for PMC and XMC mezzanine sites for functional and I/O extensions

- Pin-compatible upgrade path for Aitech C164 and C163 deployments

- Air-cooled and conduction-cooled variants

- Rugged 6U VME form factor for defense and aerospace systems

Availability and Technical Details

The C165 is now available for mission development and platform modernization programs.

For more information, visit Aitech's website.   

About Aitech

Aitech Rugged Group, Inc. ("Aitech") develops and delivers mission-critical electronics that equip defense and space organizations with faster insights, greater reliability, and the technology advantage needed to succeed in every domain. As the world's first independent provider of open-systems COTS and MOTS embedded computing solutions, Aitech combines proven computing building blocks, application-specific engineering, and long-term lifecycle support to solve complex hardware challenges.

With a portfolio of SOSA-aligned single-board computers, AI-enabled GPGPUs, rugged networking solutions, and integrated mission computing platforms, Aitech helps accelerate defense modernization while reducing program risk and complexity. For more than 40 years, Aitech has delivered mission-proven solutions across sea, land, air, and space domains. Customers include Airbus, BAE Systems, Boeing, Hindustan Aeronautics Limited (HAL), Israel Aerospace Industries (IAI), Larsen & Toubro Limited (L&T), Leonardo, Lockheed Martin, NASA, Northrop Grumman, Rafael, and Virgin Galactic.

Aitech is built for your mission. For more information, visit www.aitechsystems.com.

SOURCE Aitech

Share this article

Alfa Laval selected by Saipem to supply heat transfer technology for one of Europe's largest carbon capture projects

LUND, Sweden, Sept. 14, 2026 /PRNewswire/ -- Alfa Laval has been selected by Saipem, the EPC (Engineering, Procurement, Construction) contractor for Stockholm Exergi's BECCS (Bioenergy with Carbon Capture and Storage) project to supply heat transfer equipment for one of Europe's largest bioenergy carbon capture facilities. The project is expected to begin operations in 2028 and will capture, liquify, and permanently store up to 800,000 tonnes of CO₂ annually, representing approximately one to two percent of today's total global carbon capture capacity.

Stockholm Exergi, a leading Swedish energy provider, is taking a bold step towards net-negative emissions with the first-of-its-kind large-scale BECCS initiative set to run at Europe's largest biomass-based combined heat and power plant in Stockholm. When fully operational, the facility will capture and store CO2 from the combustion of biogenic fuels, where Alfa Laval's heat transfer solutions will play a crucial role, maximizing system efficiency and heat recovery. The project is part of Sweden's climate neutrality goals, contributing to the EU's climate strategy and positioning Stockholm Exergi as an early adopter.

"Carbon capture at this scale is one of the most demanding thermal engineering challenges in the energy transition and effective energy recovery is what ultimately makes it commercially viable," says Thomas Møller, President of the Energy Division, Alfa Laval. "Stockholm Exergi is setting a new standard for what net-negative emissions can look like at industrial scale, and we are honoured to contribute to this landmark project with our heat transfer solutions."

"The plant will require a lot of energy to capture the CO2 from the flue gas and liquify it, but with the high quality Ziepack heat exchangers from Alfa Laval, we will be able to reclaim the energy used. This energy will go back in our existing district heating system, which contributes additionally to our carbon removal targets," says Egil Nybakk, Director BECCS at Stockholm Exergi.

Alfa Laval will supply its Ziepack gas-gas interchanger alongside multiple process plate-and-frame heat exchangers, crucial for maximizing system efficiency and heat recovery, and integral parts of the core capture process. The equipment package has been selected by Saipem as part of its EPC contract for the Stockholm Exergi BECCS facility. Alfa Laval's technologies will contribute to the efficiency of the carbon capture process and support the project's ambition to become one of the world's largest facilities for the capture and permanent storage of biogenic CO2.

Contacts

Johan Lundin

Head of Investor Relations, Alfa Laval

Mobile: +46 730 46 30 90

[email protected]

Hanna Jeppsson

External Communications, Alfa Laval

Mobile: +46 767 77 61 56

[email protected]

This is Alfa Laval

Working closely with customers and partners worldwide, Alfa Laval challenges conventional thinking on engineering, quality, and innovation. Together, driving the solutions of the future, inspiring progress towards a more resourceful, less wasteful world.

Alfa Laval is set on creating positive impact in areas that society depends on, including energy, food, water, medicine, maritime transport and offshore operations. As a leading global provider of solutions in heat transfer, separation, and fluid handling, the company collaborates closely with many industries to optimize efficiency, reduce emissions and increase yields.

Alfa Laval was founded more than 140 years ago, has customers in over 100 countries, employs more than 23,500 people, and annual sales were 69.6 BSEK (6.6 BEUR) in 2025. The company is listed on Nasdaq Stockholm.

www.alfalaval.com

About the Stockholm Exergi BECCS project

Bioenergy with Carbon Capture and Storage (BECCS) is a key climate technology that generates renewable energy from biomass while capturing and permanently storing the resulting CO2.

The Stockholm Exergi plant, BECCS Stockholm, is expected to capture and permanently store up to 800,000 tonnes of biogenic CO₂ annually, making it one of the world's largest carbon removal facilities. The captured CO2 is then compressed and liquified, allowing for space-efficient underground or offshore storage.

About Stockholm Exergi

Stockholm Exergi is a Swedish energy provider in Stockholm. Today, more than 800,000 people and around 400 locations in Stockholm are connected to the district heating network, which is in turn connected to Stockholm Exergi's heating and cogeneration plants.

About Saipem

Saipem is a global leader in the engineering and construction of major projects for the energy and infrastructure sectors. The company is active across the entire CO₂ value chain, from carbon capture to transportation and storage, leveraging its engineering, technological and project execution capabilities to support clients' decarbonization objectives.

This information was brought to you by Cision http://news.cision.com.

The following files are available for download:

SOURCE Alfa Laval

Share this article

Enhanced Online Management Tool (OMT) provides customers greater control, faster service activation and actionable insight across OneWeb LEO connectivity

HOUSTON and OSNABRÜCK, GERMANY, Sept. 14, 2026 /PRNewswire/ -- Today, Eutelsat Network Solutions, the company that empowers the U.S. government and its allies to connect confidently, and G&S SatCom announced the launch of the new version of Eutelsat Network Solutions' Online Management Tool (OMT). The solution, powered by G&S SatConnect®, gives users a new level of control, agility and operational insight to plan, provision, manage and rapidly adapt their services across the OneWeb low Earth orbit (LEO) constellation. By digitizing key service management processes, the solution helps government users respond faster to changing operational and mission requirements.

Authorized users can leverage the OMT to:

- plan connectivity requirements and provision new services

- establish and manage LEO service configurations

- control organizational roles and access

- rapidly activate or adapt services as operational needs change

Flexible role- and permission-based structures also put the right capabilities and information in front of the right users, while supporting commercial agreements and service needs. The platform also supports greater flexibility in emerging operational and commercial models, including shared capacity pools and simultaneous operation models.

"Our customers told us that they wanted greater power to connect anywhere and anyhow they'd like on the planet," said Ed Slater, Chief Commercial Officer, Eutelsat Network Solutions. "Integrating the G&S SatConnect® platform into our OMT allows users to provision seamless connectivity for unmatched global coverage, performance and flexibility. It was built for the realities of government connectivity, allowing our customers to operate at speed."

The new OMT also offers a dashboard to view service, usage, statistical and performance data. This powerful insight helps users understand available capabilities and make better-informed connectivity decisions. The automation of what was once a manual process significantly reduces administrative overhead and shortens the path to an operational service.

"Government connectivity must evolve at the speed of changing mission requirements. Through G&S SatConnect®, the new OMT delivers a unified, single-pane-of-glass environment that gives

users greater operational control over how LEO services are planned, provisioned and adapted as requirements change," said David Schmitz, CEO, G&S SatCom. "We are proud to support Eutelsat Network Solutions in delivering more dynamic, scalable and mission-responsive connectivity to their customers."

To learn more about the Online Management Tool, visit EutelsatNS.us/omt.

About Eutelsat Network Solutions

Eutelsat Network Solutions delivers purpose-built satellite solutions for the U.S. government and allied partners. As the U.S. proxy company of Eutelsat, it offers access to Eutelsat's global GEO fleet and OneWeb LEO constellation, combining multi-orbit satellite capabilities with secure, reliable connectivity. Visit EutelsatNS.us for more information.

Eutelsat Network Solutions is the trade name of OneWeb Technologies Inc.

About G&S SatCom

G&S SatCom is shaping the future of satellite communications with innovative software solutions designed to unify operations across complex and evolving environments. With more than 15 years of SatCom experience, G&S SatCom empowers satellite operators, service providers, and government organizations to manage complex connectivity environments with greater security, resilience, and operational control. Its software combines visibility, automation, orchestration, and service management to simplify operations, strengthen service assurance, and enable scalable, efficient, and mission-responsive satellite services.

Visit gs-satcom.com for more information.

SOURCE Eutelsat Network Solutions

Share this article

SIRUI Wins "Best of Show", Showcases New Lenses at IBC 2026

LAS VEGAS, Sept. 14, 2026 /PRNewswire/ -- SIRUI, an imaging brand specializing in innovative lens design and technology, showcased its latest lens innovations at IBC 2026. A major highlight of the show was the Aurora 15mm F1.6 full-frame autofocus lens receiving a Best of Show Award on September 13. At Booth 12.D31, SIRUI also featured the newly launched Saturn V2, two upcoming new focal lengths in the Aurora series, and the Swift series, alongside its established Vision Prime, Iron-Star and Astra lineups.

Aurora 15mm F1.6 Receives "Best of Show" Award

SIRUI's upcoming Aurora 15mm F1.6 full-frame autofocus lens received a "Best of Show" Award during IBC 2026 on September 13.

Combining an ultra-wide 15mm focal length with a large F1.6 aperture, the lens features a 0.3m minimum focusing distance, low distortion and a compact, lightweight design. The combination of ultra-wide coverage, large aperture and portability makes it a versatile option for full-frame creators.

The lens also reflects SIRUI's focus on optical design and manufacturing, including the in-house development and production of aspherical lens elements.

New Lens Innovations at IBC 2026

SIRUI's IBC lineup featured several recent additions across anamorphic, autofocus and lightweight imaging solutions.

The Saturn V2 drew attention with its 1.6x anamorphic design, full-frame coverage and horizontal-and-vertical shooting capability, offering greater flexibility across different production formats.

The Aurora series introduced new focal lengths while maintaining a focus on compact design and image quality. The Aurora 24mm, for example, was designed for video creators with low focus breathing and a compact form factor suited to applications including vlogging, handheld video, weddings, events and documentary production.

SIRUI also showcased its upcoming Swift autofocus lens series, developed around the "Daily Carry" concept for users seeking a compact and lightweight solution for everyday shooting. Together with the Vision Prime, Iron-Star and Astra series, the lineup demonstrated SIRUI's expanding portfolio of imaging solutions.

The two new focal lengths in the Aurora series and the Swift series are set to launch progressively over the coming months. For further details, please stay tuned to SIRUI's official store.

Connecting with Creators and the Imaging Industry

Beyond product demonstrations, SIRUI engaged with filmmakers, creators, media and industry professionals throughout the show.

At the show, SIRUI was also joined by creators Sightseeing Stan, Vi-Dan, and INDIE Filmmakers, who took part in on-site talks sharing their experiences working with SIRUI lenses and their perspectives on visual storytelling. International imaging media outlet CineD also conducted an on-site interview with the SIRUI team.

SIRUI also partnered with EVOTO and HOLLYLAND on a joint on-site check-in campaign during the show.

SIRUI's participation at IBC 2026 highlighted its latest lens developments and continued engagement with the global imaging community.

About SIRUI

Founded in 2006, SIRUI is a global brand specializing in optical imaging products and dedicated to providing professional, high-quality optical and imaging solutions for photographers, filmmakers, and imaging enthusiasts. Through continuous innovation in optical technology and product design, SIRUI strives to empower creators with greater freedom to explore, create, and bring their vision to life.

Find more information about SIRUI:

Online Store: https://store.sirui.com/

Facebook: www.facebook.com/SIRUIImaging

Instagram: www.instagram.com/siruiimaging

YouTube: www.youtube.com/c/SIRUIImaging

TikTok: www.tiktok.com/@sirui.optical

SOURCE SIRUI

Share this article

Isolated Communities Overcome Severe Staffing Scarcity Through Local Mentorship as Daniels Memorial Healthcare Center Joins "All Access hosted by Andy Garcia"

An upcoming educational feature explores the critical intersection of community-driven workforce programs and modern rural hospital sustainability.

LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- The educational series "All Access hosted by Andy Garcia" will document a compelling solution to modern rural healthcare vulnerabilities during an upcoming filming session with Daniels Memorial Healthcare Center. The resulting segment will address the ongoing conflict between widespread national nursing shortages and the absolute necessity of maintaining full-service emergency facilities in isolated areas. By focusing on the mechanics of local healthcare education, the program will illustrate how specialized career pathways resolve complex clinical staffing issues. The feature will provide a practical educational roadmap for transforming rural healthcare models into self-sustaining systems that protect vulnerable civic populations.

As part of this effort, Daniels Memorial Healthcare Center is developing a new hospital to expand healthcare capacity, modernize local services, and ensure quality care remains close to home for generations to come. Central to this work is the hospital's sophisticated approach to data diversity and workforce pipeline optimization. Daniels Memorial Healthcare Center emphasizes that long-term hospital survival depends on nurturing local student talent and implementing real-time telemedicine solutions to offset geographic limitations. This methodology allows the frontier facility to maintain high-quality care standards and reduce its reliance on costly short-term contract labor. By broadcasting these insights to Public Television viewers nationwide, the segment highlights how civic engagement and technological integration work together to secure predictable clinical performance for the future.

"At Daniels Memorial Healthcare Center, rural healthcare is personal. The people we care for are our neighbors, families, coworkers, farmers, ranchers, students, and friends. Our responsibility is to make sure high-quality care remains close to home, not only for today's patients, but for future generations. This project is about more than a new building. It is about sustaining emergency care, primary care, long-term care, telemedicine, and local healthcare careers in northeast Montana." – Kody Brinton

As public health agencies and state governments confront accelerating rural hospital closures, the debate surrounding the financial efficiency of frontier medical centers intensifies. Many national health models favor consolidating services into distant urban hubs due to immediate corporate cost considerations. However, these centralized decisions frequently result in catastrophic care delays for remote residents, requiring expensive emergency transports and worsening preventable chronic illnesses. Maintaining localized, comprehensive diagnostic services resolves this conflict by providing immediate care that stabilizes patients where they live, significantly lowering ultimate systemic costs and preserving local community viability.

Furthermore, the integration of advanced diagnostic technologies in remote areas has introduced complex challenges regarding data integration and professional training. When frontier facilities rely on proprietary, distant networks to interpret critical radiology or lab work, they often encounter a clinical "black box" where processing variables remain opaque. Overcoming this operational obstacle requires a serious commitment to open technological frameworks and direct digital partnerships with major clinical hubs. When local medical practitioners have immediate, transparent access to real-time specialty consultations, they can safely make accurate, high-stakes decisions that ensure predictable, top-tier medical care.

About "All Access hosted by Andy Garcia": The "All Access hosted by Andy Garcia" series is an award-winning educational program that airs on Public Television stations across the country. Created by an experienced production team, the short-form documentaries focus on groundbreaking innovations, social trends, and inspiring stories shaping the modern world. By highlighting industry leaders, academic institutions, and visionary organizations, the program provides viewers with deep insights into complex topics ranging from technology to public healthcare systems. For more information regarding the documentary series and its upcoming broadcast schedule, please visit the official website at allaccessptv.com.

About Daniels Memorial Healthcare Center: Since its opening in 1952, Daniels Memorial Healthcare Center has provided essential, full-service medical care to northeastern Montana. Based in Scobey, the facility combines cutting-edge diagnostics, telemedicine, and emergency services to support rural families and ensure advanced healthcare remains local. Through its innovative workforce development initiatives like the "STEP (Student Training and Engagement Program) into Healthcare", the healthcare center actively trains, mentors, and employs local youth to combat industry-wide staffing shortages

"More than half of our employees grew up in the area and chose to pursue careers in their hometown," Brinton said. "We realize, however, that healthcare recruitment is very competitive, so we are working to catch the interest of young people while they are still in high school. We also have some job opportunities for high school students to get started in a healthcare career before college."

As an essential anchor for regional health, Daniels Memorial Healthcare Center continues to enrich community vitality while advancing toward a modern hospital facility. To learn more, visit danielsmemorialhealthcare.org.

SOURCE All Access

Share this article

Global Startup EXPO 2026 to Give Overseas VCs Front-door Access to Japan's Startup and Investment Ecosystem, October 5-7, 2026

TOKYO, Sept. 14, 2026 /PRNewswire/ -- The Ministry of Economy, Trade and Industry (hereinafter: "METI") will host the Global Startup EXPO 2026 (hereinafter: "GSE2026") from Monday, October 5 to Wednesday, October 7 in Osaka, Japan. As Japan's startup ecosystem expands, GSE2026 is designed as an entry point for overseas venture capital firms seeking access to emerging opportunities in Japan. Under the concept "Deeptech - from breakthrough to industry," GSE2026 connects overseas venture capital firms with Japanese startups, corporate venture capital (CVC) funds, institutional investors, and government-backed investment entities -- turning valuable connections into actionable opportunities for investment, partnership, and industrial growth.

The event goes beyond a traditional exhibition, connecting overseas investors with Japanese startups, corporate venture capital (CVC) funds, institutional investors, government-backed investment entities, and other key ecosystem participants.

Expo image 1: https://cdn.kyodonewsprwire.jp/prwfile/release/M109206/202609085515/_prw_PI1fl_5k8Re581.jpg

From Investment to Industrialization

A central focus of GSE2026 is the social implementation and industrialization of innovation, particularly in deep tech. Capital is critical, but lasting impact requires technologies and products to reach markets, generate economic value, and grow into sustainable industries. This ambition is embodied in the concept: "Deeptech - from breakthrough to industry."

Why This Matters for Global Investors

Expo image 2: https://cdn.kyodonewsprwire.jp/prwfile/release/M109206/202609085515/_prw_PI2fl_GL9wtWGu.jpg

GSE2026 offers overseas venture capital firms opportunities to engage with Japan's investment network and promising startups, including companies from METI's flagship J-Startup program and National Startup Award (NSA) awardees. For investors evaluating Japan as a sourcing market, syndication market, or long-term strategic geography, the event provides opportunities to identify potential investments, co-investment partners, and industrial collaborations.

Discover / Engage / Build

The program is structured around three stages: Discover global trends and emerging technologies; Engage with startups, investors, corporations, policymakers, and other ecosystem participants; and Build toward concrete action through business discussions, investor matchmaking, partnerships, and real-world implementation.

Featured Participants

Profiles of the Speakers:

https://cdn.kyodonewsprwire.jp/prwfile/release/M109206/202609085515/_prw_PI3fl_lPNSel20.png

Leading global investors, including Andreessen Horowitz (U.S.), New Enterprise Associates (U.S.), and Atomico (U.K.), have confirmed their participation, with additional prominent speakers and participants from Japan and around the world to be announced in the coming weeks.

For more information, the latest speaker and participant announcements, schedule updates, and registration details, please visit the official GSE2026 website: https://global-startup-expo.com/en/?utm_source=prwire&utm_medium=referral&utm_campaign=20260914&utm_content=en_url＿

SOURCE Ministry of Economy, Trade and Industry (METI)

Share this article

AMHERST, Mass., Sept. 14, 2026 /PRNewswire/ -- Myrias Optics, a world leader in wafer-level metaoptics and diffractive optical technologies, announced today that the company has been selected as the winner of the 2026 SIVA Award for "Optical Technology Breakthrough of the Year" at the China International Optoelectronic Expo.

The SIVA Awards are prominent industry honors in China's virtual and augmented reality sector. This recognition from the judges validates the potential of Myrias Optics' proprietary all-inorganic nanoimprint lithography platform to transform the scalable manufacturing of high-performance AR waveguides and meta-optics for consumer smartglasses, co-packaged optics, quantum computing, and more.

"The award reflects the innovation, commitment, and execution of the entire Myrias team—as well as the support of customers, partners, investors, and collaborators," said Myrias Optics CEO John Fijol. "We're proud of this achievement and are even more excited about what comes next as we advance our wafer-level optics technology from breakthrough innovation to high-volume commercial production."

About Myrias Optics

Myrias Optics focuses on metaoptics, diffractive optics, and AR waveguides, delivering wafer-level optical solutions that integrate advanced nanostructures with cost-efficient, high-throughput manufacturing. The company's proprietary all-inorganic nanoimprinting technology enables precision optical components with industry-leading material performance, strong yield characteristics, and a clear path to production-scale deployment.

#MyriasOptics #SIVAAwards #CIOE #OpticalTechnology #Photonics #MetaOptics #NanoimprintLithography #ARWaveguides #AdvancedManufacturing #Innovation

For more information: https://myriasoptics.com/

Contact: [email protected]

SOURCE Myrias Optics

Share this article